236

Мақолада бирламчи лейкоз беморларга диагнозни қўйиш учун биочип технологияларига асосланган молекуляр-генетик маркерлар текширилган. Тадқиқотларда ЎЛ(ўткир лейкоз) дигнози ташхиси билан даволанишни бошлаган 250 нафар беморларни жамлаб ҳисоблаганда 2600 та ген транслокациятаҳлиллари ўрганилди. Уларнинг 13 (26%) тасида химер ген(t(9;22) BCR/ABL p190(7%), t(9;22) BCR/ABL p210(14%), t(10;11) MLL/AF10(7%),t(15;17) PML/RARA bcr-2(14%), t(8;21) AML/ETO(38%), KMT2A (MLL-PTD-9)(7%) та ва KMT2A (MLL-PTD-10) (7%) ДНК молекулалари борлиги аниқланиб тегишли тавсиялар берилган

  • Internet havola
  • DOI10.26739/2181-9300-2018-4-7
  • UzSCI tizimida yaratilgan sana 25-11-2019
  • O'qishlar soni 0
  • Nashr sanasi 19-12-2018
  • Asosiy tilO'zbek
  • Sahifalar41-46
Ўзбек

Мақолада бирламчи лейкоз беморларга диагнозни қўйиш учун биочип технологияларига асосланган молекуляр-генетик маркерлар текширилган. Тадқиқотларда ЎЛ(ўткир лейкоз) дигнози ташхиси билан даволанишни бошлаган 250 нафар беморларни жамлаб ҳисоблаганда 2600 та ген транслокациятаҳлиллари ўрганилди. Уларнинг 13 (26%) тасида химер ген(t(9;22) BCR/ABL p190(7%), t(9;22) BCR/ABL p210(14%), t(10;11) MLL/AF10(7%),t(15;17) PML/RARA bcr-2(14%), t(8;21) AML/ETO(38%), KMT2A (MLL-PTD-9)(7%) та ва KMT2A (MLL-PTD-10) (7%) ДНК молекулалари борлиги аниқланиб тегишли тавсиялар берилган

Русский

В статье рассматриваются молекулярно-генетические исследования маркеровдля диагностики первичного лейкоза на основе технологий биочипов. Исследование включало 2600генных транслокации 250 пациентов с диагнозом острой лейкемии. Из них у 13(26%) выявлен химерный ген(t(9;22) BCR/ABL p190(7%), t(9;22) BCR/ABL p210(14%), t(10;11) MLL/ AF10(7%),t(15;17) PML/RARA bcr-2(14%), t(8;21) AML/ETO(38%), KMT2A (MLL-PTD-9) (7%) и KMT2A (MLL-PTD-10) (7%) )присутствиемолекул ДНК,были данны соответствующие рекомендации.

Ўзбек

The article discusses molecular genetic studies of markers for the diagnosis of primary leukemia based on biochip technology. The study included 2,600 gene translocations of 250 patients diagnosed with acute leukemia. Of these, 13 (26%) had a chimeric gene (t(9;22) BCR/ABL p190(7%), t(9;22) BCR/ABL p210(14%), t(10;11) MLL/AF10(7%),t(15;17) PML/RARA bcr-2(14%), t(8;21) AML/ ETO(38%), KMT2A (MLL-PTD-9)(7%) and KMT2A (MLL-PTD-10) (7%)) presence of DNA molecules, the relevant recommendations were given.

№ Muallifning F.I.Sh. Lavozimi Tashkilot nomi
1 KARIMOV H.Y.
2 ASMO M.D.
3 KURGANOV S.K.
4 KAYUMOV A.A.
5 ISROILOV A.A.
6 BOBOEV K.T.
№ Havola nomi
1 1.Amanda C. Wintersand Kathrin M. Bernt. MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches. FrontPediatr. 2017; 5: 4.Р 3-25. doi: 10.3389/fped.2017.00004.
2 2.Annette Fasan, Claudia Haferlach, Karolina Perglerovà, Wolfgang Kern, and TorstenHaferlach. Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse. Haematologica. 2017 Jun; 102(6): e222–e224.doi:10.3324/haematol.2016.162206.
3 3.Chai-AdisaksophaC,LamW,HillisC.Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.Leuk Lymphoma.2016;57(6):1300-10. doi: 10.3109 / 10428194.2015.1091929
4 4.Daniel A. Arber, AttilioOrazi, Robert Hasserjian, Jürgen Thiele, Michael J. Borowitz, Michelle M. Le Beau, Clara D. Bloomfield, Mario Cazzola and James W. Vardiman. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 2016 127:2391-2405. https://doi.org/10.1182/blood-2016-03-643544
5 5.Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.JAMA Oncol. 2016; 2 (5): 625-632. DOI: 10,1001 / jamaoncol.2015.5932
6 6.Haery L, Thompson RC, Gilmore TD. Histone acetyltransferases and histone deacetylases in Band T-cell development, physiology and malignancy. GenesCancer. 2015;6:184–213. doi: 10.18632/ genesandcancer.65.
7 7.HartmutDöhner, ElihuEstey, David Grimwade, Sergio Amadori, Frederick R. Appelbaum, Thomas Büchner, HervéDombret, Benjamin L. Ebert, Pierre Fenaux, Richard A. Larson, Ross L. Levine, Francesco Lo-Coco, Tomoki Naoe, DietgerNiederwieser, Gert J. Ossenkoppele, Miguel Sanz, Jorge Sierra, Martin S. Tallman, Hwei-Fang Tien, Andrew H. Wei, Bob Löwenberg, and Clara D. Bloomfield. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26; 129(4): 424–447.doi:10.1182/blood-2016-08-733196.
8 8.Hua Yang, Sai Huang, Cheng-Ying Zhu, Li Gao, Hai-Yan Zhu, Na Lv, Yu Jing, and Li Yu. The Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements. MedSciMonit. 2016; 22: 2315–2323.doi:10.12659/MSM.899186.
9 9.Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res ClinHaematol. 2014;27(1):3–9.doi: 10.1016 / j.beha.2014.04.006.
10 10.Madan V, Shyamsunder P, Han L, et al.Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016;30(12):2430. doi: 10.1038/leu.2016.237.
11 11.Mandoli A, Singh AA, Prange KHM, Tijchon E, Oerlemans M, Dirks R, Menno TH, Wierenga ATJ, Jansses-Megens EM, Berentsen K, Sharifi N, Kim B, Matarese F, Nguyen LN, Hubner NC, Rao NA, van den Akker E, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs. CellReports. 2016 Nov 15;17:1–14.doi: 10.1016 / j.celrep.2016.08.082
12 12.María-José Bañuls , Sergi B. Morais , Luis A. Tortajada-Genaro , and ÁngelMaquieira, Microarray Technology: Methods and Applications, Methods in Molecular Biology, vol. 1368, © Springer Science+Business Media New York 2016. p 37-51, DOI 10.1007/978-1-4939-3136-1_4
13 13.Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood. 2012 Nov 8;120:4038–48.doi: 10.1182 / blood-2012-05-429050.
14 14.Rieko Taniguchi, Hideki Muramatsu, Yusuke Okuno, Kyogo Suzuki, Satoshi Obu, Masahiro Nakatochi, TeppeiShimamura, Yoshiyuki Takahashi, YasuoHorikoshi, Kenichiro Watanabe and Seiji Kojima. Comprehensive genetic analysis of donor cell derived leukemia with KMT2Arearrangement. Pediatric Blood & Cancer. 2017. №4 P 1-5. DOI: 10.1002/pbc.26823.
15 15.Tamai H, Inokuchi K. 11q23/MLL acute leukemia: update of clinical aspects. J ClinExpHematop. 2010;50:91–98.
16 16.ValentP,HadzijusufovicE,SchernthanerGH,etal.Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015;125(6):901-6.doi: 10.1182 / blood-2014-09-594432.
17 17.Руководство по применению набора реагентов для выявления и идентификации хромосомных транслокаций при острых и хронических лейкозах методом гибридизации на биологических микрочипах «лк-биочип». 2009 год. www.biochip-imb.ru/attachments/article/27. pdf
18 18.http://www.interlabservice.ru/catalog/reagents/?sid=1403&id=6489
19 19.https://omim.org/entry/102578?search=PML/RARA&highlight=pml%20pmlrara%20rara
20 20.https://omim.org/entry/133435?search=AML/ETO&highlight=amleto%20aml%20eto
21 21.https://omim.org/entry/151410_ BCR / ABL FUSION GENE
22 22.https://omim.org/entry/159555_MLL/AF10
23 23.https://omim.org/search/?index=entry&search=leukemia&sort=score+desc%2C+prefix_ sort+desc&start=139&limit=10
Kutilmoqda